... which are designed to direct immune T cells to cancer cells, while incorporating a masking peptide to reduce binding to healthy tissues and prevent ...
... which are designed to direct immune T cells to cancer cells, while incorporating a masking peptide to reduce binding to healthy tissues and prevent ...
Lonza cited increasing demand for clinical-stage manufacturing and said “the acquisition of the site will provide additional cGMP capacity and will ...
... therapies to target solid tumors, announces that the US Patent and Trademark Office has granted US Patent no 9,775,892, Peptide mixture.
ITCA 650 is an implantable pump designed to deliver a continuous supply of the glucagon-like peptide-1 agonist exenatide, which is the active ...
Lutathera, a peptide receptor radionuclide therapy, is the company's first drug approved as a therapeutic drug for GEP-NET. However, Advanced ...
Peptilogics, a Pittsburgh, PA- and San Jose, CA-based pre-clinical stage company utilizing an innovative peptide platform to treat multidrug-resistant bacterial infections, closed a $5.5m Series A financing.
Backers included Peter Thiel, Stefan Roever, BlueTree Ventures and others. Read more...
BAGSVAERD, Denmark I September 29, 2017 I Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Fiasp® (fast-acting insulin aspart), a new fast-acting mealtime insulin, for the treatment of adults with diabetes. The FDA's decision comes after Fiasp® in clinical trials demonstrated benefits for people in need of improved overall glucose control. Read more...
Peter Thiel has invested in Peptilogics. The Paypal founder contributed to the $5.5 million series A Peptilogics put together to advance its lead treatment for multidrug-resistant bacterial infections toward an IND.
Thiel joined with Stefan Roever, BlueTree Ventures and others to power Peptilogics to the series A. The financing follows the generation of preclinical data Peptilogics says suggest its platform and, in particular, its lead candidate can take out a broad spectrum of resistant bacteria. Those data have put Peptilogics in a position to work toward filing an IND next year. Read more...
Hanmi Pharmaceutical has presented two drug candidates employing its proprietary Lapscovery platform technology at the European Association for the Study of Diabetes.
The two therapies in development are a triple agonist for non-alcoholic fatty liver disease and Parkinson’s, and a glucagon analog for treating congenital hyperinsulinism.
Both drugs employ Hanmi’s Lapscovery — short for Long Acting Protein and Peptide Discovery — which extends the life of a biologic drug within the body, extending its efficacy and potency. Hanmi presented the animal testing results of the two drugs and their efficacy during this year’s EASD conference in Lisbon, Portugal earlier this month.
A triple agonist is a biologic agent that simultaneously activates glucagon, an energy metabolism booster, as well as GLP-1 and GIP, which aid insulin uptake and release.
A glucagon analog instigates glucose synthesis by acting as a glucagon inhibitor. It has shown an ability to elevate blood sugar levels, suggesting it can become a potential treatment for hyperinsulinism, Hanmi said.
Both drugs have been developed as drugs requiring a single injection per week, according to the Korean drugmaker. Looking ahead, it plans to continue expanding the application of its Lapscovery technology into new disease areas.
By Sohn Ji-young (jys@heraldcorp.com)
Protagenic Therapeutics, Inc. (OTCQB:PTIX) announced today that experiments conducted at independent contract research organizations have demonstrated that PT00114, its novel drug candidate for the treatment of stress-related mental disorders, has rapid and long-lasting activity. Read more...